Cannabis Studies Certificate

Never before has a book been compiled on cannabis brands and the consumers they appeal to. Once an underground commodity, with legalization in more and more states and countries, cannabis is now marketed under a variety of national brands, each with its own unique approach to targeting consumers. The global legal cannabis market was valued at US$17.7 billion in 2019 and is expected to reach US$73.6 billion in 2027. Celebrities, athletes, politicians, and large corporations alike are investing and competing in this fast-paced industry. But what makes a cannabis brand successful? What techniques do companies use to brand and market their products? What segments have been established? InBranding Bud: The Commercialization of Cannabis, David Paleschuck answers these questions, digging deep into this evolving industry to uncover what both small companies and large corporations are doing to introduce their products to the hearts and minds of cannabis consumers. The results of his exploration may surprise you. Branding Bud showcases the exciting range of products that cannabis consumers will be able to buy in a local dispensary once legalization comes to their state. The book offers a comprehensive overview and contextualization of this new segment, examining the multitude of emerging brands, their creative assets, and the strategies behind them, and the political, legal, and cultural aspects of cannabis that inform the brand landscape of today. This book is a must-read for entrepreneurs, investors, marketers, designers, and anyone interested in the rapidly growing cannabis industry.

Cannabis sativa is the scientific name for the widely used drug commonly known as marijuana. Marijuana is the most commonly used illegal drug in the United States as well as in many other countries. Considered a "soft" drug, it is a naturally growing plant that is harvested as its crude product for use. Other familiar names for marijuana are weed, dope, pot, hemp, cannabis, and reefer. Marijuana contains tetrahydrocannabinol (THC), which is a mind altering substance that is generally smoked, but also can be taken orally or as oil on the skin in order to receive a "high." New laws regarding the marijuana's legalisation have led to more questions and increased interest in the effect marijuana has on its users. Chapter One of this book discusses differences across motivation variables and marijuana use. Chapter Two compares the medical necessity of marijuana to the political agenda. Chapter Three examines the evidence for and against the medical use of marijuana, and the effects and implications of its recent legalisation in several states especially with regard to its use by college-age young adults. Chapter Four examines the issues surrounding legalisation and teen use and the policy steps that might be taken to effectively communicate the risks to adolescents amidst an ever more socially acceptable climate. Chapter Five discusses the recent rise of legally sold marijuana, the risks of use, arguments in support of mandating warnings on packages of legally sold marijuana, the likely benefits and costs of mandating warnings, ways of evaluating proposed and actual warnings, and specific recommended warnings. Chapter Six exhibit how and the extent to which federal government marijuana regulation and policy contributes to disparities in arrest, in particular for African Americans of lower socioeconomic standing. This book ends with a commentary on aims to answer the question of whether marijuana and video games can engender "real" addictions in a way that bridges the gap between scientific and colloquial understandings of problem use.

Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for medical conditions or retail sales at the state level and 4 states have legalized both the medical and recreational use of cannabis. These landmark changes in policy have impacted cannabis use patterns and perceived levels of risk. However, despite this changing landscape, evidence regarding the short- and long-term health effects of cannabis use remains elusive. While a myriad of studies have examined cannabis use in all its various forms, often these research conclusions are not appropriately synthesized, translated for, or communicated to policy makers, health care providers, state health officials, or other stakeholders who have been charged with influencing and enacting policies, procedures, and laws related to cannabis use. Unlike other controlled substances such as alcohol or tobacco, no accepted standards for safe use or appropriate dose are available to help guide individuals as they make choices regarding the issues of if, when, where, and how to use cannabis safely and, in regard to therapeutic uses, effectively. Shifting public sentiment, conflicting and impeded scientific research, and legislative battles have fueled the debate about what, if any, harms or benefits can be attributed to the use of cannabis or its derivatives, and this lack of aggregated knowledge has broad public health implications. The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis. This report provides a research agenda "outlining gaps in current knowledge and opportunities for providing additional insight into these issues "that summarizes and prioritizes pressing research needs.

Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment is the first book to take an interdisciplinary approach to the understanding of cannabis use and misuse. Recent worldwide trends toward decriminalizing marijuana for medical use have increased legal use of the drug and recreational use remains high, making cannabis one of the most commonly used drugs. Cannabis has a wide range of adverse neurological effects, and use and abuse can lead to physical, social, and psychopathological issues that are multifarious and complex. Effective understanding and treatment requires knowledge of the drug's effects from across scientific disciplines. This book provides an overview of the biological and pharmacological components of the cannabis plant, outlines its neurological, social, and psychopathological effects, assists in the diagnosis and screening for use and dependency, and aids researchers in developing effective treatments for cannabis-related issues and disorders. Fully illustrated, with contributions from internationally recognized experts, it is the go-to resource for neuroscientists, pharmacologists, pathologists, public-health workers, and any other researcher who needs an in-depth and cross-disciplinary understanding of cannabis and its effects.

As the largely illicit cannabis market transitions to a legal, regulated industry, the'canna-curious'and experienced industry participants alike are experiencing the harsh truth: Making a fortune in the legal cannabis industry is a challenge made even more difficult by a complex patchwork of state and federal laws. The Cannabis Business clears the confusion around topics such as the distinction between hemp and cannabis and why it matters for consumers and regulators, why CBD isn't completely legal in the U.S., why and how states differ in their licensing processes, and how deal structuring is impacted by state regulations. Written by attorneys from the nation's leading cannabis law and policy firm, this comprehensive primer on all things cannabis law is a must-have for anyone seeking to understand the major practical legal issues facing the cannabis industry in the U.S.

Learn how to get in on the ground floor of the booming cannabis industry with this comprehensive guide Investing in Cannabis: The Next Great Investment Opportunity examines the rapidly expanding world of cannabis investment. Written by a renowned expert in "vice investing," Investing in Cannabis takes an in-depth look at all aspects of publicly traded stocks in the cannabis industry for medical or recreational use, including: CBD / hemp companies Cannabis oil extraction Cannabis cultivation / agriculture companies Biotech / pharmaceutical companies This book focuses on the status and history of cannabis legalization plus concrete examples that every day investors can use to make intelligent and informed investments in any sector of the modern, legal cannabis industry. With an emphasis on good lists and data, the author guides readers through the ins and outs of the booming cannabis industry and attempts to distinguish between future breakout success stories and future busts. Investing in Cannabis is perfect for any person or institutional investor seeking to diversify their portfolio to include investments in this up-and-coming industry.

    From the leading authority on marijuana--a man who has served as White House advisor on drugs to three different administrations and who NBC News once called "the prodigy of drug politics"--comes the remarkable and shocking exposé about how 21st century pot, today's new and highly potent form of the drug, is on the rise, spreading rapidly across America by an industry intent on putting rising profits over public health. Smokescreen: What the Marijuana Industry Doesn't Want You to Know examines the inside story behind the headlines, containing accounts from Sabet's time in the Obama administration to stunning revelations from whistleblowers speaking out for the first time. What it finds is how the marijuana industry is running rampant without proper oversight, leaving Americans' health seriously at risk. Included are interviews with industry insiders who reveal the hidden dangers of a product they had once worshipped. Also contained in these pages are insights from a major underground-market dealer who admits that legalization is hastening the growth of the illicit drug trade. And more to the heart of the issue are the tragic stories of those who have suffered and died as a result of marijuana use, and in many cases, as a result of its mischaracterization. Readers will learn how power brokers worked behind the scenes to market marijuana as a miracle plant in order to help it gain widespread acceptance and to set the stage for the lucrative expansion of recreational pot. The author of this compelling first-person narrative leading the national fight against the legalization of cannabis through his nonprofit, Smart Approaches to Marijuana (aka SAM) is Kevin Sabet. As a policy advisor to everyone from county health commissioners to Pope Francis, and a frequent public speaker on television, radio and through other media outlets, his analysis is consistently relied upon by those who recognize what's at stake as marijuana lobbyists downplay the risks of massive commercialization. A book several years in the making, filled with vivid characters and informed by hundreds of interviews and scores of confidential documents, Sabet's Smokescreen lays bare the unvarnished truth about marijuana in America.

It only took five years for two brothers-in-law to create a billion-dollar, award-winning, take-no-prisoners cannabis company called HEXO. How did they do it? That's the story. From early roadblocks and devastating personal and financial setbacks to explosive growth and some of the biggest cannabis deals in global history, Billion Dollar Start-Up not only recounts the HEXO story but the history of Canada's momentous road to legalization. In this part fast-paced memoir, part high-octane business book, writer and journalist Julie Beun gives us an intimate look at the life of a start-up and the ferocious entrepreneurial drive it takes to succeed -- written in real-time, as the story unfolded. Throughout history, there have been fewer than 100 Canadians who have started a company and lived to see it become worth one billion dollars. Adam Miron and Sébastien St-Louis are two of them. This is their story.

"The inside scoop on how marijuana landed on Main Street . . . and why it's coming soon to a city near you."-Katie Couric From gleaming dispensaries stocked with elegantly wrapped edibles to the array of CBD lotions and oils for sale at your local drugstore to tastemaker Martha Stewart cooking up marijuana munchies on prime-time television, one thing is clear- Pot has fully shed its stoner image. In this deeply reported journey into the new world of legal cannabis, award-winningreporter Heather Cabot takes readers on the road with Snoop Dogg and his business partner Ted Chung as they roll out the star's own brand of bud; to California wine country, where chefs and vintners are ushering in a new age of elevated dining; on wild adventures with marijuana mogul Beth Stavola, for whom fending off shady characters is just another day at the office; and to rural Canada to meet the Willy Wonka of Weed. Drawing on exclusive interviews with some of the biggest names in the world of cannabis, Cabot's book explores the confluence of social, economic, and political forces that have brought marijuana into the mainstream. Among them, outrage over the racial injustice of U.S. drug laws, the booming self-care industry catering to stressed-out professionals and busy parents in search of better sleep and more sex, seniors clamoring for natural alternatives to opioids to manage their aches and pains, and tens of millions of investor dollars fueling a frenetic "green rush" mentality. The story of an astonishing rebranding,The New Chardonnayexplores how a plant that was once the subject of multimillion-dollar public service announcements came to spark new culinary trends; inspire new uses for health, beauty, and wellness; and generate hundreds of thousands of jobs and untold tax revenue-all while remaining federally illegal in America.

Two economists take readers on a tour of the economics of legal and illegal weed, showing where cannabis regulation has gone wrong and how it could do better. Cannabis "legalization" hasn't lived up to the hype. Across North America, investors are reeling, tax collections are below projections, and people are pointing fingers. On the business side, companies have shut down, farms have failed, workers have lost their jobs, and consumers face high prices. Why has legal weed failed to deliver on many of its promises? Can Legal Weed Win? takes on the euphoric claims with straight dope and a full dose of economic reality. This book delivers the unadulterated facts about the new legal segment of one of the world's oldest industries. In witty, accessible prose, economists Robin Goldstein and Daniel Sumner take readers on a whirlwind tour of the economic past, present, and future of legal and illegal weed. Drawing upon reams of data and their own experience working with California cannabis regulators since 2016, Goldstein and Sumner explain why many cannabis businesses and some aspects of legalization fail to measure up, while others occasionally get it right. Their stories stretch from before America's first medical weed dispensaries opened in 1996 through the short-term boom in legal consumption that happened during COVID-19 lockdowns. Can Legal Weed Win? is packed with unexpected insights about how cannabis markets can thrive, how regulators get the laws right or wrong, and what might happen to legal and illegal markets going forward.